Sugi Predict

Sugi Predict / Compounds / SCHEMBL1053992

SCHEMBL1053992

SCHEMBL1053992

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1cc(Cl)nc(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 1/20 0.36
▸ HSP90AB1 P08238 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MT-CO2 P00403 1/20 0.35
▸ S1PR2 O95136 1/20 0.35
▸ SOS1 Q07889 1/20 0.35
▸ STK17B O94768 1/20 0.35
▸ STK17A Q9UEE5 1/20 0.35
▸ PAX8 Q06710 1/20 0.34
▸ SYK P43405 1/20 0.33
▸ ACACB O00763 1/20 0.32
▸ ACACA Q13085 1/20 0.32
▸ ATR Q13535 1/20 0.32
▸ LCK P06239 1/20 0.32
▸ CACNA1G O43497 1/20 0.32
▸ CACNA1B Q00975 1/20 0.32
▸ CACNA1C Q13936 1/20 0.32
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13746242 0.92 HSP90AA1 (0.34) HSP90AA1HSP90AB1KMT2ALMNAMT-CO2
SCHEMBL31602247 0.88 TAS1R3 (0.38) HSP90AA1HSP90AB1KMT2ALMNAMT-CO2
SCHEMBL23060528 0.88 SOS1 (0.34) HSP90AA1HSP90AB1KMT2ALMNAMT-CO2
SCHEMBL26624314 0.88 SOS1 (0.34) HSP90AA1HSP90AB1KMT2ALMNAMT-CO2
SCHEMBL29185138 0.85 GPR119 (0.38) HSP90AA1HSP90AB1KMT2ALMNAMT-CO2
SCHEMBL15595426 0.85 PAX8 (0.44) HSP90AA1HSP90AB1KMT2ALMNAMT-CO2
SCHEMBL24150872 0.84 BRD4 (0.33) HSP90AA1HSP90AB1MT-CO2S1PR2SOS1
SCHEMBL10329957 0.84 STK17B (0.32) S1PR2STK17BSTK17AACACBACACA
SCHEMBL23060388 0.83 SOS1 (0.32) HSP90AA1HSP90AB1SOS1CACNA1GCACNA1B
SCHEMBL26624298 0.83 SOS1 (0.32) HSP90AA1HSP90AB1SOS1CACNA1GCACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 — — US claimed
WO-2026101924-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2026-05-15 — — WO disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-07-19 — — US disclosed
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-07-19 — — US disclosed
EP-2459558-A2 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 — — EP disclosed
WO-2011014795-A2 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 — — WO disclosed
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 — — US disclosed
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 — — US disclosed
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 — — US disclosed
EP-2250169-A1 PYRIDO [4, 3-D]PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2010-11-17 — — EP disclosed
WO-2009099801-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2009-08-13 — — WO disclosed
WO-2009099801-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSP90AA1 4176/4885HSP90AB1 4084/4885KMT2A 445/4885
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN HSP90AA1 1072/4885HSP90AB1 671/4885KMT2A 1710/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSP90AA1 4176/4885HSP90AB1 4084/4885KMT2A 445/4885
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS ZAP70, FLT3, LCK HSP90AA1 3256/4885HSP90AB1 2902/4885KMT2A 2967/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HSP90AA1 4176/4885HSP90AB1 4084/4885KMT2A 445/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSP90AA1 4176/4885HSP90AB1 4084/4885KMT2A 445/4885
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF KRAS, NRAS, HRAS HSP90AA1 4150/4885HSP90AB1 4121/4885KMT2A 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.